Study guide

Kawasaki disease and follow-up

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Kawasaki disease and follow-up

Key Takeaways Explain This Topic AI

RCH criteria allow diagnosis with at least four days of fever and compatible features.

IV immunoglobulin is central to Kawasaki treatment.

Echocardiographic follow-up is needed even after fever resolves.

Last updated: October 2026

Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)

Kawasaki disease is an acute, self-limiting systemic vasculitis of medium-sized muscular arteries. It has an extraordinary predilection for the coronary arteries , representing the leading cause of acquired paediatric heart disease in Australia and other developed nations. Approximately 85% of cases occur in children between 6 months and 5 years of age.

Classical Diagnostic Criteria

Kawasaki diagnosis is clinical and can be made with at least four days of fever plus compatible features under the RCH pathway. Experienced assessment can recognise earlier or incomplete disease. Do not wait rigidly for five days when concern is high; involve paediatrics/cardiology and assess coronary involvement.

Bilateral Non-Exudative Conjunctival Injection : Painless, diffuse erythema of the bulbar conjunctiva that characteristically spares the limbus (the avascular border surrounding the iris). There is no purulent discharge or corneal ulceration.

Oral Cavity and Lip Changes : Erythema, severe drying, cracking, and bleeding fissures of the lips; diffuse erythema of the oropharyngeal mucosa; and a prominent "strawberry tongue" (hyperplastic fungiform papillae protruding through a denuded or erythematous lingual coating).

Polymorphous Cutaneous Rash : Widespread maculopapular, erythema multiforme-like, or scarlatiniform eruption predominantly involving the trunk, extremities, and groin; characteristically non-vesicular.

Extremity Changes :

Acute phase : Marked erythema of the palms and soles with indurative, painful, non-pitting oedema of the dorsum of hands and feet (infant refuses to bear weight).

Convalescent phase : Characteristic sheet-like periungual desquamation (peeling around the fingernails and toenails) beginning 2 to 3 weeks after fever onset.

Cervical Lymphadenopathy : Typically unilateral , involving the anterior cervical chain, with at least one node measuring ≥ 1.5 cm \ge 1.5\text{ cm} ≥ 1.5 cm in diameter; firm, non-fluctuant, and minimally tender.

Incomplete (Atypical) Kawasaki Disease

Frequently encountered in young infants under 6 months of age , who paradoxically face the highest risk of developing giant coronary aneurysms.

Incomplete Kawasaki disease: Consider persistent unexplained fever with fewer features, especially in infants. Laboratory and echocardiographic assessment supports the pathway; consult paediatrics/cardiology without waiting rigidly for a calendar threshold.

Cardiac Complications and Management

Coronary Artery Aneurysms : Untreated Kawasaki disease results in coronary artery aneurysms in 20% to 25% of children. Aneurysms predispose to acute coronary thrombosis, myocardial infarction, and sudden cardiac death. Giant aneurysms (internal diameter > 8 mm > 8\text{ mm} > 8 mm or Z-score ≥ 10 \ge 10 ≥ 10 ) carry the highest lifetime risk of thrombosis and stenosis.

First-Line Pharmacotherapy :

Intravenous Immunoglobulin (IVIG) : Administered as a single high-dose infusion of 2 g/kg 2\text{ g/kg} 2 g/kg over 10 to 12 hours. Must be initiated within the first 10 days of fever onset (and at any time thereafter if fever or systemic inflammation persists). Early IVIG reduces the incidence of coronary artery abnormalities from 25% to under 3% to 5% .

Aspirin (Oral) : Dual dosing phases in Australia:

Kawasaki treatment: Senior paediatric/cardiology management includes IVIG 2 g/kg and low-dose aspirin; RCH uses 5 mg/kg daily for thrombosis prevention. Higher acute aspirin doses have not demonstrated improved coronary outcomes, so a mandatory high-dose-then-low-dose regimen is not universal Australian practice. High-risk patients may receive adjunct corticosteroids.

Aspirin: RCH uses 5 mg/kg daily, with duration guided by coronary findings and cardiology; avoid a mandatory high-dose acute regimen.

Transthoracic Echocardiography : Performed at diagnosis (baseline), repeated at 2 weeks , and at 6 to 8 weeks post-presentation to measure coronary internal luminal diameters and calculate body surface area-adjusted Z-scores.

Kawasaki follow-up example

A child has four days of fever, conjunctival injection, oral changes, rash and extremity changes. Arrange senior paediatric/cardiology assessment and echocardiography; do not wait for a fifth fever day if the clinical picture is compelling. Incomplete disease can occur without every feature, especially in younger infants. Treat under the pathway, assess response and arrange coronary follow-up. Persistent fever after initial IVIG needs specialist reassessment of inflammation and alternative diagnoses. Explain aspirin use and bleeding precautions, and check timing of subsequent live vaccines after IVIG using the current immunisation guidance.

Fever response after treatment

If fever returns after initial Kawasaki treatment, reassess with the specialist team for ongoing inflammation, coronary involvement, treatment resistance and alternative diagnoses. Do not automatically repeat the same medicines without reviewing response and risks. Families need a clear follow-up schedule and instructions for deterioration, chest symptoms, persistent fever or poor intake. Echocardiographic assessment and later surveillance are determined by disease course; a normal first scan does not remove every follow-up requirement. Coordinate vaccination advice after IVIG, particularly the timing of live vaccines, using the current Handbook and the dose/indication received.

Primary references (checked 7 October 2026): RCH Kawasaki disease ; RCH meningitis/encephalitis .